141 related articles for article (PubMed ID: 9041753)
21. Implementing a Fee-for-Service Cervical Cancer Screening and Treatment Program in Cameroon: Challenges and Opportunities.
DeGregorio G; Manga S; Kiyang E; Manjuh F; Bradford L; Cholli P; Wamai R; Ogembo R; Sando Z; Liu Y; Sheldon LK; Nulah K; Welty T; Welty E; Ogembo JG
Oncologist; 2017 Jul; 22(7):850-859. PubMed ID: 28536303
[TBL] [Abstract][Full Text] [Related]
22. Mega Hpv laboratories for cervical cancer control: Challenges and recommendations from a case study of Turkey.
Gultekin M; Karaca MZ; Kucukyildiz I; Dundar S; Keskinkilic B; Turkyilmaz M
Papillomavirus Res; 2019 Jun; 7():118-122. PubMed ID: 30878532
[TBL] [Abstract][Full Text] [Related]
23. Expenditure and resource utilisation for cervical screening in Australia.
Lew JB; Howard K; Gertig D; Smith M; Clements M; Nickson C; Shi JF; Dyer S; Lord S; Creighton P; Kang YJ; Tan J; Canfell K
BMC Health Serv Res; 2012 Dec; 12():446. PubMed ID: 23216968
[TBL] [Abstract][Full Text] [Related]
24. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.
Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M
Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.
Bidus MA; Maxwell GL; Kulasingam S; Rose GS; Elkas JC; Chernofsky M; Myers ER
Obstet Gynecol; 2006 May; 107(5):997-1005. PubMed ID: 16648402
[TBL] [Abstract][Full Text] [Related]
26. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
de Sanjose S; Quint WG; Alemany L; Geraets DT; Klaustermeier JE; Lloveras B; Tous S; Felix A; Bravo LE; Shin HR; Vallejos CS; de Ruiz PA; Lima MA; Guimera N; Clavero O; Alejo M; Llombart-Bosch A; Cheng-Yang C; Tatti SA; Kasamatsu E; Iljazovic E; Odida M; Prado R; Seoud M; Grce M; Usubutun A; Jain A; Suarez GA; Lombardi LE; Banjo A; Menéndez C; Domingo EJ; Velasco J; Nessa A; Chichareon SC; Qiao YL; Lerma E; Garland SM; Sasagawa T; Ferrera A; Hammouda D; Mariani L; Pelayo A; Steiner I; Oliva E; Meijer CJ; Al-Jassar WF; Cruz E; Wright TC; Puras A; Llave CL; Tzardi M; Agorastos T; Garcia-Barriola V; Clavel C; Ordi J; Andújar M; Castellsagué X; Sánchez GI; Nowakowski AM; Bornstein J; Muñoz N; Bosch FX;
Lancet Oncol; 2010 Nov; 11(11):1048-56. PubMed ID: 20952254
[TBL] [Abstract][Full Text] [Related]
27. [Costs of population cervical cancer screening program in Poland between 2007-2009].
Spaczyński M; Karowicz-Bilinska A; Kedzia W; Molińska-Glura M; Seroczyński P; Januszek-Michalecka L; Rokita W; Nowak-Markwitz E
Ginekol Pol; 2010 Oct; 81(10):750-6. PubMed ID: 21117303
[TBL] [Abstract][Full Text] [Related]
28. Cervical cancer screening by cytology and human papillomavirus testing during pregnancy in French women with poor adhesion to regular cervical screening.
Brun-Micaleff E; Coffy A; Rey V; Didelot MN; Combecal J; Doutre S; Daurès JP; Segondy M; Boulle N
J Med Virol; 2014 Mar; 86(3):536-45. PubMed ID: 24114972
[TBL] [Abstract][Full Text] [Related]
29. The impact on women's health and the cervical cancer screening budget of primary HPV screening with dual-stain cytology triage in Belgium.
Tjalma WAA; Kim E; Vandeweyer K
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():171-181. PubMed ID: 28081908
[TBL] [Abstract][Full Text] [Related]
30. Cervical cancer prevention in Australia: Planning for the future.
Saville AM
Cancer Cytopathol; 2016 Apr; 124(4):235-40. PubMed ID: 26619381
[TBL] [Abstract][Full Text] [Related]
31. Organization of screening programs in developing countries with reference to screening for cancer of the uterine cervix in India.
Luthra UK; Rengachari R
IARC Sci Publ; 1986; (76):273-88. PubMed ID: 3570411
[TBL] [Abstract][Full Text] [Related]
32. Recommendations for cervical cancer prevention in Asia Pacific.
Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
[TBL] [Abstract][Full Text] [Related]
34. Colposcopy, cervicography, speculoscopy and endoscopy. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial.
van Niekerk WA; Dunton CJ; Richart RM; Hilgarth M; Kato H; Kaufman RH; Mango LJ; Nozawa S; Robinowitz M
Acta Cytol; 1998; 42(1):33-49. PubMed ID: 9479322
[TBL] [Abstract][Full Text] [Related]
35. Cost-Effectiveness of High-Risk Human Papillomavirus Testing With Messenger RNA Versus DNA Under United States Guidelines for Cervical Cancer Screening.
Ting J; Smith JS; Myers ER
J Low Genit Tract Dis; 2015 Oct; 19(4):333-9. PubMed ID: 26225945
[TBL] [Abstract][Full Text] [Related]
36. Criteria for organized cervical screening programs. Special emphasis on The Netherlands program.
Hanselaar AG
Acta Cytol; 2002; 46(4):619-29. PubMed ID: 12146020
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of costs and benefits of advances in cytologic technology. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial.
Melamed MR; Hutchinson ML; Kaufman EA; Schechter CB; Garner D; Kobler TP; Krieger PA; Reith A; Schenck U
Acta Cytol; 1998; 42(1):69-75. PubMed ID: 9479325
[TBL] [Abstract][Full Text] [Related]
38. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
[TBL] [Abstract][Full Text] [Related]
39. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
Goldie SJ; O'Shea M; Diaz M; Kim SY
Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
[TBL] [Abstract][Full Text] [Related]
40. Australian women's needs and preferences for information about human papillomavirus in cervical screening.
McCaffery K; Irwig L
J Med Screen; 2005; 12(3):134-41. PubMed ID: 16156944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
